{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:24:58Z","timestamp":1785353098753,"version":"3.55.0"},"reference-count":63,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dement. neuropsychol."],"abstract":"<jats:p>ABSTRACT Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder accompanied by behavioral and personality changes and\/or language deterioration. Its behavioral variant (bvFTD) is the main clinical presentation.  Objective:  This study aims to investigate the treatment alternatives for bvFTD available so far.  Methods:  We conducted a narrative review of bvFTD treatment options. We used PubMed and Lilacs databases with the terms \u201cfrontotemporal dementia\u201d or \u201cbehavioral variant frontotemporal dementia\u201d combined with \u201ctreatment,\u201d \u201cpharmacological treatment,\u201d or \u201cdisease-modifying drugs.\u201d  Results:  The articles retrieved and selected in the research pointed out that there is no specific treatment approved for bvFTD so far. The current proposals are limited to handle the cardinal behavioral symptoms of the disorder. Disease-modifying drugs are under development and may be promising, especially in the monogenic presentations of FTD.  Conclusions:  There are numerous approaches to treat the core symptoms of bvFTD, most of them based on low-quality research. To date, there are no drugs with a disease-specific therapeutic recommendation for bvFTD. Treatments are often investigated guided by primary psychiatric disorders with similar symptoms and should be chosen by the predominant symptom profile.<\/jats:p>","DOI":"10.1590\/1980-57642021dn15-030004","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T13:28:29Z","timestamp":1632144509000},"page":"331-338","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of the behavioral variant of frontotemporal dementia: a narrative review"],"prefix":"10.1590","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-8872","authenticated-orcid":false,"given":"Leandro Boson","family":"Gambogi","sequence":"first","affiliation":[{"name":"Behavioral and Cognitive Neurology Research Group,  Brazil; Postgraduate Program in Neurosciences,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-7099","authenticated-orcid":false,"given":"Henrique Cerqueira","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Behavioral and Cognitive Neurology Research Group,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-9722","authenticated-orcid":false,"given":"Leonardo Cruz de","family":"Souza","sequence":"additional","affiliation":[{"name":"Behavioral and Cognitive Neurology Research Group,  Brazil; Postgraduate Program in Neurosciences,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-6990","authenticated-orcid":false,"given":"Paulo","family":"Caramelli","sequence":"additional","affiliation":[{"name":"Behavioral and Cognitive Neurology Research Group,  Brazil; Postgraduate Program in Neurosciences,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2021,9]]},"reference":[{"issue":"4","key":"ref1","first-page":"416","article-title":"The Lund and Manchester Groups","volume":"57","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary D","year":"1998","journal-title":"Neurology"},{"issue":"Pt 9","key":"ref3","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky K","year":"2011","journal-title":"Brain"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S1980-57642013DN70100004","article-title":"Neuropathology of frontotemporal lobar degeneration: a review","volume":"7","author":"Bahia VS","year":"2013","journal-title":"Dement Neuropsychol"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/09540261.2013.776523","article-title":"The epidemiology of frontotemporal dementia","volume":"25","author":"Onyike CU","year":"2013","journal-title":"Int Rev Psychiatry"},{"issue":"12","key":"ref6","article-title":"Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration","volume":"90","author":"Seo SW","year":"2018","journal-title":"Neurology"},{"issue":"16","key":"ref7","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/01.wnl.0000319702.37497.72","article-title":"Distinct genetic forms of frontotemporal dementia","volume":"71","author":"Seelaar H","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1590\/1980-57642015dn93000003","article-title":"The genetics of monogenic frontotemporal dementia","volume":"9","author":"Takada LT","year":"2015","journal-title":"Dement Neuropsychol"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-160852","article-title":"Factors underpinning caregiver burden in frontotemporal dementia differ in spouses and their children","volume":"56","author":"Kaizik C","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jamaneurol.2014.3781","article-title":"Criminal behavior in frontotemporal dementia and Alzheimer disease","volume":"72","author":"Liljegren M","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNN.0000000000000217","article-title":"Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review","volume":"33","author":"Trieu C","year":"2020","journal-title":"Cogn Behav Neurol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","article-title":"Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study","volume":"49","author":"Moretti R","year":"2003","journal-title":"Eur Neurol"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","article-title":"Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial","volume":"172","author":"Deakin JB","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"Lebert F","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.npp.1300886","article-title":"Methylphenidate (\u2018Ritalin\u2019) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia","volume":"31","author":"Rahman S","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4088\/JCP.v69n1219a","article-title":"Stimulant treatment of frontotemporal dementia in 8 patients","volume":"69","author":"Huey ED","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz A","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","article-title":"Memantine in behavioral variant frontotemporal dementia: negative results","volume":"23","author":"Vercelletto M","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"Pt 9","key":"ref19","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awr171","article-title":"The effects of oxytocin on social cognition and behaviour in frontotemporal dementia","volume":"134","author":"Jesso S","year":"2011","journal-title":"Brain"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer AL","year":"2013","journal-title":"Lancet Neurol"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000369811","article-title":"Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study","volume":"15","author":"Pardini M","year":"2015","journal-title":"Neurodegener Dis"},{"issue":"5-6","key":"ref22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000445873","article-title":"Agomelatine improves apathy in frontotemporal dementia","volume":"16","author":"Callegari I","year":"2016","journal-title":"Neurodegener Dis"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4088\/JCP.v58n0506","article-title":"Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors","volume":"58","author":"Swartz JR","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/gps.894","article-title":"Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide","volume":"18","author":"Adler G","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000076343","article-title":"Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients","volume":"17","author":"Ikeda M","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"14","key":"ref26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","article-title":"Rivastigmine in frontotemporal dementia: an open-label study","volume":"21","author":"Moretti R","year":"2004","journal-title":"Drugs Aging"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/mds.20465","article-title":"Stereotypical movements and frontotemporal dementia","volume":"20","author":"Mendez MF","year":"2005","journal-title":"Mov Disord"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/gps.1973","article-title":"A 6-month, open-label study of memantine in patients with frontotemporal dementia","volume":"23","author":"Diehl-Schmid J","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/WAD.0b013e318197852f","article-title":"An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration","volume":"23","author":"Boxer AL","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","article-title":"Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia","volume":"20","author":"Herrmann N","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/gps.602","article-title":"Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation","volume":"17","author":"Moretti R","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/153331750301800410","article-title":"Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: a 24-month follow-up of 68 patients","volume":"18","author":"Moretti R","year":"2003","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WAD.0b013e318047df5d","article-title":"Memantine for behavioral disturbances in frontotemporal dementia: a case series","volume":"21","author":"Swanberg MM","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez MF","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1468-1331.2007.02032.x","article-title":"Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?","volume":"15","author":"Czarnecki K","year":"2008","journal-title":"Eur J Neurol"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00004714-200006000-00018","article-title":"Case of pick\u2019s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone","volume":"20","author":"Curtis RC","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/155005940403500212","article-title":"Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study","volume":"35","author":"Goforth HW","year":"2004","journal-title":"Clin EEG Neurosci"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15622970601016538","article-title":"Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism","volume":"8","author":"Fellgiebel A","year":"2007","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/WNN.0b013e31816bdf73","article-title":"Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report","volume":"21","author":"Cruz M","year":"2008","journal-title":"Cogn Behav Neurol"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JCP.0b013e31823f91b9","article-title":"Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine","volume":"32","author":"Poetter CE","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1155\/2013\/547853","article-title":"Topiramate for abnormal eating behaviour in frontotemporal dementia","volume":"27","author":"Singam C","year":"2013","journal-title":"Behav Neurol"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","article-title":"A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia","volume":"66","author":"Huey ED","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11910-012-0302-7","article-title":"Diagnosis and management of behavioral issues in frontotemporal dementia","volume":"12","author":"Manoochehri M","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1533317509356692","article-title":"Off-label medication use in frontotemporal dementia","volume":"25","author":"Bei H","year":"2010","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1533317512447887","article-title":"Use of antidementia drugs in frontotemporal lobar degeneration","volume":"27","author":"Lopez-Pousa S","year":"2012","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"12","key":"ref46","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher AR","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1345\/aph.1P341","article-title":"Use of psychostimulants in patients with dementia","volume":"44","author":"Dolder CR","year":"2010","journal-title":"Ann Pharmacother"},{"key":"ref48","first-page":"CD012197","article-title":"Pharmacological interventions for apathy in Alzheimer\u2019s disease","volume":"5","author":"Ruthirakuhan MT","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11940-014-0319-0","article-title":"Treatment of frontotemporal dementia","volume":"16","author":"Tsai RM","year":"2014","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pscychresns.2007.07.003","article-title":"Serotonin-1A receptors in frontotemporal dementia compared with controls","volume":"156","author":"Lanct\u00f4t KL","year":"2007","journal-title":"Psychiatry Res"},{"issue":"Pt 7","key":"ref51","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/brain\/awv133","article-title":"Improving response inhibition systems in frontotemporal dementia with citalopram","volume":"138","author":"Hughes LE","year":"2015","journal-title":"Brain"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ana.20365","article-title":"Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration","volume":"57","author":"Franceschi M","year":"2005","journal-title":"Ann Neurol"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.pnpbp.2005.11.005","article-title":"Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder","volume":"30","author":"El Mansari M","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"ref54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.22244","article-title":"Eating and hypothalamus changes in behavioral-variant frontotemporal dementia","volume":"69","author":"Piguet O","year":"2011","journal-title":"Ann Neurol"},{"issue":"5","key":"ref55","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.69.5.636","article-title":"Effects of topiramate on cognitive function","volume":"69","author":"Thompson PJ","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7 Pt 2","key":"ref56","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1523\/JNEUROSCI.15-07-05169.1995","article-title":"Dopaminergic correlates of motivated behavior: importance of drive","volume":"15","author":"Wilson C","year":"1995","journal-title":"J Neurosci"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/bs.pbr.2016.05.007","article-title":"The role of dopamine in the pathophysiology and treatment of apathy","volume":"229","author":"Chong TT","year":"2016","journal-title":"Prog Brain Res"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0000000000001133","article-title":"Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability","volume":"84","author":"Finger EC","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"ref59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/appi.focus.20160018","article-title":"A clinical guide to frontotemporal dementias","volume":"14","author":"Ljubenkov PA","year":"2016","journal-title":"Focus"},{"issue":"7-8","key":"ref60","doi-asserted-by":"crossref","DOI":"10.1111\/jocn.14007","article-title":"Nonpharmacological approaches for behavioural and psychological symptoms of dementia in older adults: A systematic review of reviews","volume":"27","author":"Legere LE","year":"2018","journal-title":"J Clin Nurs"},{"issue":"3","key":"ref61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/09638288.2017.1387614","article-title":"The tailored activity program (TAP) to address behavioral disturbances in frontotemporal dementia: a feasibility and pilot study","volume":"41","author":"O\u2019Connor CM","year":"2019","journal-title":"Disabil Rehabil"},{"issue":"9","key":"ref62","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/14656566.2019.1598377","article-title":"Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs","volume":"20","author":"Logroscino G","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"ref63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41582-020-0330-x","article-title":"Development of disease-modifying drugs for frontotemporal dementia spectrum disorders","volume":"16","author":"Panza F","year":"2020","journal-title":"Nat Rev Neurol"}],"container-title":["Dementia &amp; Neuropsychologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/dn\/v15n3\/1980-5764-dn-15-03-331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T13:29:13Z","timestamp":1632144553000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1980-57642021000300331&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["S1980-57642021000300331"],"URL":"https:\/\/doi.org\/10.1590\/1980-57642021dn15-030004","relation":{},"ISSN":["1980-5764","1980-5764"],"issn-type":[{"value":"1980-5764","type":"electronic"},{"value":"1980-5764","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}